Congress · Basel, Switzerland
World Biosimilar Congress 2016
Health
Key numbers
- Editions on record
- 2first in 2016
About World Biosimilar Congress
In 2015, we saw the crescendo of the Amgen versus Sandoz case after many months of appeals. Along with that legal case, many more are still ongoing in the biosimilar sector. This year also provided a milestone in the ongoing discussions and debates on naming conventions with both the US FDA and WHO providing their individual guidance on such issues.
But what does all this mean for future biosimilar development?
Many questions need answering in order for biosimilars to reach the market success that the industry knows it can attain.
* Is there finally confidence from healthcare professionals in administering biosimilar drugs?
*Has the science of biosimilar development reached a level regulators are happy with in terms of characterisation and comparison?
* Are pricing strategies adequately supporting biosimilar development?
Event Website: http://bit.ly/2aCdFcH
Register now: http://bit.ly/2arqSFS
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2017 | 31 Oct – 1 Nov 2017 | Kongress Zentrum Basel Basel, Switzerland | — | — |
| 2016 | 14–15 Nov 2016 | Kongress Zentrum Basel Basel, Switzerland | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.